Vertex reported a sharp uptick in sales of Casgevy, its CRISPR‑based, gene‑edited therapy developed with CRISPR Therapeutics, driving a notable improvement in the company’s recent earnings picture. Sales of the gene‑edited treatment more than tripled quarter‑over‑quarter, positioning Casgevy as a commercial bright spot within Vertex’s portfolio. The rebound underscores commercial traction for an approved CRISPR‑based product and validates investment in gene‑editing platforms. Analysts flagged the therapy’s growth as a stabilizing factor for Vertex’s revenue mix and an early commercial proof point for genome‑editing medicines.